Management of Postoperative Nausea and Vomiting in Ambulatory Surgery The Big Little Problem
|
|
- Julianna Walker
- 6 years ago
- Views:
Transcription
1 Management of Postoperative Nausea and Vomiting in Ambulatory Surgery The Big Little Problem Mary Keyes, MD KEYWORDS Postoperative nausea and vomiting PONV prophylaxis PONV in ambulatory surgery KEY POINTS The Consensus Guidelines for Managing Postoperative Nausea and Vomiting (PONV) provides an evidence-based management strategy for clinicians. Although the exact cause of PONV is unknown, many receptors, pathways, and neurotransmitters are likely involved. Because of the multitude of inputs that may be causal, single therapies are often inadequate. An individual s risk for PONV is best predicted by using a simplified risk score of independent predictors: female gender, nonsmoking status, history of PONV or motion sickness, and postoperative opioid use. Although some types of surgery, plastic surgery among them, are associated with higher PONV risk, risk scores that include type of surgery provide no greater predictive value. Strategies that avoid inhaled anesthetics such as total intravenous anesthesia (TIVA), elimination of nitrous oxide, and minimal opioid use reduce risk. Multimodal regimens involving TIVA with propofol, combination antiemetic prophylaxis, hydration, and nonnarcotic analgesics, are the most effective way to prevent PONV in high-risk patients. Postdischarge nausea and vomiting is common in ambulatory surgery patients. Those who have nausea in the postanesthesia care unit (PACU) are particularly at risk. Which agents in addition to dexamethasone are effective remains to be determined. Considerable progress has been made in the management of postoperative nausea and vomiting (PONV) since it was labeled the big little problem over 20 years ago by Kapur. 1 Although usually self-limited, it is distressing to patients who, in some studies, state they would pay up to $ out of pocket for a drug to avoid it. 2 PONV can lead to dehydration, electrolyte disturbances, and the inability to take vital oral medications and fluids after surgery. The act of vomiting can cause suture disruption, lead to hematoma formation, and be a risk factor for pulmonary aspiration. Its occurrence often delays discharge from ambulatory settings and is a leading cause of unanticipated hospital admission escalating health care costs. With most surgeries now being done on an outpatient or ambulatory basis, considerable attention is being given to this issue. The Consensus Guidelines for Managing Postoperative Nausea and Vomiting authored by an international panel of experts created an evidencebased management strategy for clinicians. 3 These UCLA Department of Anesthesiology, Ronald Reagan UCLA Medical Center, 757 Westwood Plaza, Suite 3325, Los Angeles, CA , USA address: mkeyes@mednet.ucla.edu Clin Plastic Surg 40 (2013) /13/$ see front matter Published by Elsevier Inc. plasticsurgery.theclinics.com
2 448 Keyes guidelines have been the foundation for the improved understanding and recent advances gained regarding this common, undesirable perioperative experience. However, there is still room for improvement, particularly in the area of postdischarge nausea and vomiting (PDNV), which occurred in up to 37% of ambulatory patients in a recently published study. 4 PATHOPHYSIOLOGY OF NAUSEA AND VOMITING Various stimuli that produce nausea and vomiting converge in an area of the medulla known as the emetic center. This center is not a discrete nucleus but rather a collection of neurons controlled by a central pattern generator. Input to the emetic center comes from a variety of pathways: the visceral afferent nerves of the gastrointestinal tract, the chemoreceptor trigger zone (CTZ), the cerebral cortex, and the vestibular apparatus. Each of these systems is modulated by specific receptors and neurotransmitters. The CTZ is located in the fourth ventricle of the brainstem but, because of its uniquely permeable membrane, it is outside the blood-brain barrier, which allows detection of toxins and drugs in the circulation. Stimulation of dopamine, opioid, histamine, acetylcholine, serotonin type 3 receptors, or neurokinin-1 receptors in the emetic center initiates the vomiting reflex. Therapies that interfere with each of these neurotransmitter-receptor interactions are used to prevent nausea and vomiting in clinical practice. Because of the multitude of inputs that may be causal in the production of nausea and vomiting, single therapies are often inadequate. ASSESSING RISK FOR PONV The important first step in managing PONV is to assess risk for each patient. In doing so, there are 3 categories of factors to consider: Patient-specific factors: 1. Female gender 2. Nonsmoking status 3. History of PONV or motion sickness Anesthesia-related factors: 1. Use of volatile anesthetics 2. Use of nitrous oxide 3. Perioperative opioid use Surgery-related factors: 1. Duration and invasiveness of surgery 2. Type of surgery A simplified risk score of independent predictors by Apfel and colleagues 5 has gained widespread recognition and implementation by anesthesia providers. Although some types of surgery (plastic, strabismus, gynecologic, laparoscopic, urologic) are known to be associated with a higher PONV risk, risk scores that include type of surgery provide no greater predictive value than a simplified version. For example, hysterectomy is known to have a higher PONV risk. It may be that this increased risk is a reflection of the patient population who are female (the strongest risk factor) rather than the surgery itself. Patients having plastic surgery are predominantly women, making them inherently at higher risk. The simplified risk score for an adult having a balanced inhalational anesthetic consists of the following 4 factors: female gender, nonsmoking status, previous history of PONV or motion sickness, and postoperative opioid use. The presence of 1 risk factor correlates with a risk of 20% for PONV. Each additional risk factor adds 20%, so that patients with all 4 have an 80% risk of developing PONV (Fig. 1). REDUCING RISK There are often strategies that can be incorporated into the anesthesia and surgical plan to reduce the probability of developing PONV: 1. Total intravenous anesthesia (TIVA) with propofol reduces PONV risk about 19% from a patient s baseline risk. 6 Impediments to the use of propofol have been cost, the lack of ability to monitor depth of anesthesia, and the need for an infusion pump. Propofol is now a generic drug, making the cost difference between it and a volatile agent much less significant. The cost savings gained in having less PONV and improved patient satisfaction may justify the increased cost. 2. Nitrous oxide use is a risk factor for PONV, although not as significant as the volatile anesthetic agents. Both propofol anesthesia and inhalational anesthesia are more emetogenic when N 2 O is used in combination. There is no difference in emetogenicity between isoflurane, desflurane, and sevoflurane. One of the findings of the International Multicenter Protocol to assess Antiemetic Combinations Trial (IMPACT) was that, by eliminating N 2 O as the carrier gas, PONV risk is reduced by about 12% Minimization of perioperative opioids reduces PONV risk. Infiltration with local anesthetics and the use of alternative nonnarcotic analgesics are opioid sparing. Ketorolac has been available and in use for more than a decade.
3 Postoperative Nausea and Vomiting 449 Fig. 1. Risk factors for developing PONV. (From Apfel CC, Läärä E, Koivuranta M, et al. A simplified risk score for predicting postoperative nausea and vomiting: conclusions from cross-validations between two centers. Anesthesiology 1999;91(3): ; with permission.) Some surgeons are reluctant to use it because it causes inhibition of platelet aggregation by inhibiting cyclooxygenase. Although the increased incidence of bleeding is small, when surgical outcome is jeopardized, many surgeons avoid using it. Intravenous acetaminophen (Ofirmev) was approved by the US Food and Drug Administration (FDA) in late Most studies of Ofirmev use report less opioid consumption and a lower percentage of patients requiring rescue medications. The rapid blood level achieved by the intravenous route provides an excellent alternative or adjunct for those patients requiring mild to moderate pain relief. 4. Regional anesthesia is associated with a marked reduction in PONV risk compared with general inhalational anesthesia by avoiding exposure to volatile anesthetics and narcotics. PONV PROPHYLAXIS Serotonin Antagonists The serotonin antagonists have become one of the foundation drug classes in the treatment of PONV. Much of what is known about antiemetic prophylaxis has come from therapies effective in chemotherapy-induced nausea and vomiting. Cytotoxic chemotherapy is associated with release of serotonin from the gut. This released serotonin may stimulate vagal afferents in the gut through 5-hydroxytryptamine (5-HT3) receptors and initiate vomiting. Serotonin is also found throughout the central nervous system, including the CTZ. The 5-HT3 receptor antagonists (5-HT3-RAs) include ondansetron (Zofran), dolasetron (Anzemet), granisetron (Kytril), and, most recently, palonosetron (Aloxi). All are approved for use in the United States. In general, all are considered safe and equally effective. Ondansetron was the first of its class and the most widely studied. The most common side effects (headache, constipation, and diarrhea) occur at a low rate. These drugs are not sedating and do not cause extrapyramidal side effects, which makes them particularly useful. It is recommended that ondansetron 4 mg (and other drugs in this class) be given 20 to 30 minutes before the end of surgery to provide prophylaxis for 4 to 6 hours after surgery in the case of ondansetron. The variable chemical structures of each of these drugs may explain the minor differences in dose response and duration of action. Palonosetron is unique in this group, with a long half-life of about 40 hours, which may make it useful in the prevention of PDNV. Steroids Dexamethasone is effective in the management of PONV. It has a slow onset of action and consequently the recommendation is to administer it immediately following induction of anesthesia. Although the mechanism of action is not completely known, it is thought that steroids inhibit prostaglandin synthesis centrally or lead to endorphin release. The Society for Ambulatory Anesthesia (SAMBA) guidelines endorse the use of 4 to 5 mg of dexamethasone, whereas other studies have determined that higher doses (8 mg) are more effective. 7,8 There seems to be no clinical toxicity associated with the use of dexamethasone for PONV prophylaxis. Dopamine Antagonists There are several groups of drugs that are dopamine antagonists. The two most common in the
4 450 Keyes class of butyrophenones are droperidol and haloperidol. In addition to blocking D 2 receptors, these drugs cause alpha blockade, which can lead to sedation and extrapyramidal symptoms, although not commonly at the small doses given for PONV prophylaxis (0.625/1.25 mg). The efficacy of droperidol as a cost-effective antiemetic has been well established. It would be considered by many anesthesia providers to be first-line therapy if not for the black-box warning imposed by the FDA in The concern regarding prolongation of the QT interval has been implicated in the development of torsades de pointes; although evidence of this effect with small antiemetic doses is lacking. Most other currently available antiemetics also cause QT prolongation, including the phenothiazines, antihistamines, and the 5- HT3-RA, ondansetron. Hypothermia and the duration of general anesthesia are also associated with QT prolongation. There has been a drastic decline in the use of droperidol since this warning. In our institution, droperidol use is limited to high-risk patients who will have cardiac monitoring for at least 2 hours from the time of drug administration. Although effective, haloperidol can only be given by the intramuscular route because of similar concerns of cardiac dysrhythmia. The phenothiazines, promethazine (Phenergan) and prochlorperazine (Compazine) are commonly used antiemetics. Because of numerous adverse effects such as agitation, somnolence, and extrapyramidal effects, their use is not considered first-line therapy. A retrospective review comparing the efficacy of a repeat dose of ondansetron for established PONV versus 6.25 mg of promethazine showed greater efficacy with promethazine. Higher doses of promethazine did not increase efficacy. 9 This finding supports the recommendations by experts to choose a drug from another class when the first drug fails, because the receptors targeted by the first drug given are already blocked. The use of intravenous promethazine is associated with a small but serious risk of venous thrombosis and inflammation. It is essential to ensure that promethazine is administered slowly in a wellfunctioning intravenous line. Although commonly used, Compazine has not been well studied for effectiveness. The benzamide, metoclopramide, blocks both central and peripheral D 2 receptors. At the commonly used 10-mg dose, numerous studies have failed to show antiemetic efficacy and it is therefore not recommended for PONV prophylaxis. 10 Higher doses may be effective but lead to an unacceptably high incidence of extrapyramidal symptoms. Antihistamines Diphenhydramine (Benadryl) is an H 1 blocker with antiemetic effects at the recommended dose of 1 mg/kg intravenously. Its use in PONV prophylaxis has not been well studied. The anticholinergic side effects of dry mouth, blurred vision, and urinary retention limit its use. Cholinergic Antagonists Scopolamine and atropine block cholinergic muscarinic emetic receptors in the central nervous system. Because of its weaker antiemetic properties and resultant tachycardia, atropine is not used for PONV prophylaxis. Transdermal scopolamine has been shown to be effective as an antiemetic. 11 Its anticholinergic side effects of blurred vision, dry mouth, and restlessness, as well as its 2-hour to 4-hour onset of action, limit its use. It may be useful in combination with other agents in high-risk patients and in the prevention of PDNV. MANAGEMENT STRATEGIES The IMPACT study established that the three most commonly used antiemetics, ondansetron 4 mg, dexamethasone 4 mg, and droperidol 1.25 mg, are equally effective for PONV prophylaxis. 6 Various combinations of these three interventions were examined and each antiemetic was found to act independently and to reduce risk by about 26%. It was also shown that the efficacy of these drugs is primarily dependent on the baseline risk rather than on which antiemetic was given. The first antiemetic has the greatest impact on reducing risk; additional antiemetics in a combination regimen add less and less benefit as the baseline risk decreases, as shown in Table 1. Also shown in the table is that those with the greatest risk benefit the most from PONV prophylaxis, whereas those with already low risk, benefit little. For example, a patient with no risk factors has a 10% baseline risk for PONV. If this patient receives 1 intervention, the risk for PONV is reduced only to about 7%, which demonstrates why prophylaxis is not generally recommended in this group of patients (Fig. 2). Low Risk These patients have 0 to 1 risk factor for PONV. A reasonable approach to these patients is to either use a single antiemetic agent or none at all if the procedure is short, not invasive, and there are no serious medical or surgical consequences to consider. Dexamethasone and the 5-HT3-RA are considered first-line therapy. Because dexamethasone is not immediately effective, it should be
5 Postoperative Nausea and Vomiting 451 Table 1 Estimated PONV incidence as a function of baseline risk, assuming each intervention reduces relative risk by 26% (values given as %) given following induction. Ondansetron (or other 5- HT3-RAs) are reserved for rescue treatment; this group of drugs is effective for established PONV. 12 Intermediate Risk Number of Interventions None a One Two Three Four a The baseline risk levels of 10%, 20%, 40%, 60%, and 80% reflect 0, 1, 2, 3, and 4 risk factors considered in a simplified risk score. From Apfel CC, Korttila K, Abdalla M, et al. A factorial trial of six interventions for the prevention of postoperative nausea and vomiting. N Engl J Med 2004;350:2449; with permission. These patients have 2 to 3 risk factors. For example, a nonsmoking woman has 2 risk factors from the outset. Female gender is the strongest risk factor for PONV and the risk persists long after menopause. It is generally recommended that patients with intermediate risk have at least 2 interventions. These interventions could be either combination antiemetics, such as dexamethasone and a 5-HT3-RA, or a propofol-based anesthetic with dexamethasone. Measures to minimize opioid use, such as the use of local anesthetics when appropriate and nonnarcotic analgesics (Ketorolac or Ofirmev), reduce risk. If ondansetron (or other 5-HT3-RA) has been used during the course of anesthesia and the patient develops PONV in the PACU (postanesthesia care unit), a drug from another class should be chosen because the serotonin receptors are already blocked. Promethazine at a dose of 6.25 mg may be used as rescue therapy in this case. 9 Droperidol could also be given if the patient can be monitored on a cardiac monitor for 2 hours. A second dose of ondansetron can be given if 4 to 6 hours have passed since the initial dose. High Risk Patients with 3 or 4 risk factors require a multimodal approach because no combination of 2 or even 3 antiemetics eliminates the possibility of developing PONV. Scuderi and colleagues 13 introduced the concept of multimodal therapy in high-risk patients, which included propofol and remifentanil intravenous anesthesia (TIVA), dual antiemetic prophylaxis with droperidol (0.625 mg) and dexamethasone (10 mg), ketorolac, hydration with 25 ml/kg total fluids, and 1 mg ondansetron at the end of the case. Only 1 patient required treatment of nausea in Fig. 2. Risk factors and PONV management strategy.
6 452 Keyes the PACU and this was treated with 12.5 mg of diphenhydramine. This study was able to show that it is possible to decrease PONV to a low level in high-risk patients but it requires the increased expertise needed to perform TIVA rather than the relative ease of providing general anesthesia with a vaporizer. PDNV In a recently published prospective multicenter study of ambulatory surgery patients having general anesthesia, Apfel and colleagues found a remarkably high incidence of 37% for nausea and/or vomiting following discharge. This is in contrast to the approximately 21% of the same group having nausea and/or vomiting in the PACU. 4 They found 5 independent risk factors for PDNV: female gender, age less than 50 years, history of PONV, opioids administered in the PACU, and nausea in the PACU. These risks factors are similar to those found to predict PONV. The most significant finding is that patients who experience nausea in the PACU have a 3-fold higher risk for developing PDNV. Ondansetron administered during surgery and a TIVA with propofol are not protective for PDNV because of the short half-lives of both of these drugs. The agents or combinations of agents that will prove useful in PDNV prevention remain unclear at this time. In the study by Apfel and colleagues, 4 dexamethasone significantly reduced PDNV. The first FDA-approved neurokinin-1 receptor antagonist aprepitant (Emend) has been found to be superior to ondansetron in the prevention of vomiting in the first 24 to 48 hours following surgery. 14 Aprepitant is well tolerated and comes in oral and intravenous forms that may be useful when other agents have failed. The second-generation 5-HT3-RA palonosetron has a significantly longer half-life than ondansetron and consequently may be efficacious in reducing PDNV. SUMMARY Identifying those patients with the highest risk leads to the greatest success in reducing PONV by modifying the anesthetic plan to decrease baseline risk, and implementing the appropriate use of prophylaxis. The strategies that will be effective in the reduction of PDNV are currently under investigation. REFERENCES 1. Kapur PA. The big little problem [editorial]. Anesth Analg 1991;73: Gan T, Sloan F, Dear G, et al. How much are patients willing to pay to avoid postoperative nausea and vomiting? Anesth Analg 2001;92: Gan TJ, Meyer T, Apfel CC, et al. Consensus guidelines for managing postoperative nausea and vomiting. Anesth Analg 2003;97: Apfel CC, Philip BK, Cakmakkaya OS, et al. Who is at risk for postoperative nausea and vomiting after ambulatory surgery? Anesthesiology 2012;117: Apfel CC, Läärä E, Koivuranta M, et al. A simplified risk score for predicting postoperative nausea and vomiting: conclusions from cross-validations between two centers. Anesthesiology 1999;91(3): Apfel CC, Korttila K, Abdalla M, et al. A factorial trial of six interventions for the prevention of postoperative nausea and vomiting. N Engl J Med 2004;350: Gan TJ, Meyer T, Apfel CC, et al. Society for ambulatory anesthesia guidelines for the management of postoperative nausea and vomiting. Anesth Analg 2007;105: Elhakim M, Nafie M, Mahmoud K, et al. Dexamethasone 8 mg in combination with ondansetron 4 mg appears to be the optimal dose for the prevention of nausea and vomiting after laparoscopic cholecystectomy. Can J Anaesth 2002; 49(9): Habib AS, Reuveni J, Taguchi A, et al. A comparison of ondansetron with promethazine for treating postoperative nausea and vomiting in patients who received prophylaxis with ondansetron: a retrospective database analysis. Anesth Analg 2007;104(3): Henzi I, Walder B, Tramer MR. Metochlopramide in the preventions of postoperative nausea and vomiting: a quantitative systematic review of randomized placebo-controlled studies. Br J Anaesth 1999; 83(5): Carlisle J, Stevenson C. Drugs for preventing postoperative nausea and vomiting. Cochrane Database Syst Rev 2006;(3):CD Kazemi-Kjellberg F, Henzi I, Tramer MR. Treatment of established postoperative nausea and vomiting: a quantitative systematic review. BMC Anesthesiol 2001;1(1): Scuderi PE, James RL, Harris L, et al. Multimodal Antiemetic Management Prevents Early Postoperative Vomiting After Outpatient Laparoscopy. Anesth Analg 2000;91(6): Gan TJ, Apfel CC, Kovac A, et al. A randomized, double-blind comparison of the NK1 antagonist, aprepitant, versus ondansetron for the prevention of postoperative nausea and vomiting. Anesth Analg 2007;105(5):
DEXAMETHASONE WITH EITHER GRANISETRON OR ONDANSETRON FOR POSTOPERATIVE NAUSEA AND VOMITING IN LAPAROSCOPIC SURGERY
DEXAMETHASONE WITH EITHER GRANISETRON OR ONDANSETRON FOR POSTOPERATIVE NAUSEA AND VOMITING IN LAPAROSCOPIC SURGERY Alia S. Dabbous *, Samar I. Jabbour-Khoury **, Viviane G Nasr ***, Adib A Moussa ***,
More informationGastrointestinal and urinary complications in the postoperative period
The 13 th Annual Perioperative Medicine Summit Fort Lauderdale, Florida Gastrointestinal and urinary complications in the postoperative period Dan Hunt, MD Professor of Medicine Director, Division of Hospital
More informationGI Pharmacology -4 Irritable Bowel Syndrome and Antiemetics. Dr. Alia Shatanawi
GI Pharmacology -4 Irritable Bowel Syndrome and Antiemetics Dr. Alia Shatanawi 11-04-2018 Drugs used in Irritable Bowel Syndrome Idiopathic, chronic, relapsing disorder characterized by abdominal discomfort
More informationMeasure Abbreviation: PONV 01 (MIPS 430)
Measure Abbreviation: PONV 01 (MIPS 430) *PONV 01 is built to the specification outlined by the Merit Based Incentive Program (MIPS) 430: Prevention of Post-Operative Nausea and Vomiting (PONV) Combination
More informationNausea and vomiting after surgery
Sébastien Pierre MD Rachel Whelan Matrix reference 1A02 Key points 5-Hydroxytrytamine type 3 (5-HT 3 ) receptor antagonists, and specifically ondansetron, are the most commonly used antiemetics for both
More informationNQS Domain: Patient Safety. Measure Type: Process
Measure Abbreviation: PONV 02 (MIPS 463) *PONV 02 is built to the specification outlined by the Merit Based Incentive Program (MIPS) 463: Prevention of Post-Operative Vomiting (POV) Combination Therapy
More informationMeasure Abbreviation: PONV 01 (MIPS 430)
Measure Abbreviation: PONV 01 (MIPS 430) *PONV 01 is built to the specification outlined by the Merit Based Incentive Program (MIPS) 430: Prevention of Post-Operative Nausea and Vomiting (PONV) Combination
More information2018 Perioperative Management of PDNV
2018 Perioperative Management of PDNV Edward C. Adlesic, DMD Assistant Professor Oral and Maxillofacial Surgery Assistant Professor Dental Anesthesiology University of Pittsburgh School of Dental Medicine
More informationPalonosetron vs Ondansetron for prevention of postoperative nausea and vomiting in...
IOSR Journal of Dental and Medical Sciences (IOSR-JDMS) e-issn: 2279-0853, p-issn: 2279-0861.Volume 15, Issue 2 Ver. XI (Feb. 2016), PP 45-49 www.iosrjournals.org Palonosetron vs Ondansetron for prevention
More informationEditor s key points. M. S. Green*, P. Green, S. N. Malayaman, M. Hepler, L. J. Neubert and J. C. Horrow
British Journal of Anaesthesia 109 (5): 716 22 (2012) Advance Access publication 24 July 2012. doi:10.1093/bja/aes233 Randomized, double-blind comparison of oral aprepitant alone compared with aprepitant
More informationPostoperative Nausea and Vomiting: Update on Prevention, Rescue, and Novel Strategies
Postoperative Nausea and Vomiting: Update on Prevention, Rescue, and Novel Strategies No conflicts of interest to disclose (sadly) 2 March 2016 Melissa Brooks Peterson, MD Department of Anesthesiology/Pediatric
More informationPONV : The big little problem. Dr.Dewinter
PONV : The big little problem. Dr.Dewinter Introduction Definition Pathophysioloy Ponv risk factors and prognosis systems Antiemetics Ponv scheme Conclusion Introduction Incidence of PONV : 30 % Most common
More informationPage 1 of 6 PATIENT PRESENTATION PROPHYLAXIS. No risk factors from the categories
Page 1 of 6 PATIENT PRESENTATION PROPHYLAXIS risk factors from the categories listed below more than one drug prophylaxis (see Appendix A for antiemetic choices) Patient scheduled for surgery Assess patient
More informationLow-dose Granisetron for the Prevention of Postoperative Nausea and Vomiting
Low-dose Granisetron for the Prevention of Postoperative Nausea and Vomiting John D. Bridges, BS (Pharm)* Cindy B. Nettle, PharmD* Vijaya J. Dugirrala MD Katie J. Suda, PharmD Kevin W. Garey, PharmD *Baptist
More informationGeneric (Brand) Strength & Dosage form Fml Limit Cost per Rx Notes 5-HT3 Antagonists
MEDICATION COVERAGE POLICY PHARMACY AND THERAPEUTICS ADVISORY COMMITTEE POLICY Nausea LAST REVIEW 9/11/2018 THERAPEUTIC CLASS Gastrointestinal Disorders REVIEW HISTORY 12/16, 11/15, 11/07 LOB AFFECTED
More informationNausea and Vomiting in Palliative Care
Nausea and Vomiting in Palliative Care Definitions Nausea - an unpleasant feeling of the need to vomit Vomiting - the expulsion of gastric contents through the mouth, caused by forceful and sustained contraction
More informationDECONTAMINATION AGENTS and ANTIEMETICS *** This material won t be covered in lecture, but you are responsible for it***
Decontamination and Antiemetics Med 5724 Page 1 of 8 DECONTAMINATION AGENTS and ANTIEMETICS *** This material won t be covered in lecture, but you are responsible for it*** REFERENCES: Katzung (9th ed.)
More informationNew Drugs in Pediatric Anesthesia
New Drugs in Pediatric Anesthesia Anne M. Lynn MD Seattle Children s Hospital University of Washington School of Medicine There s nothing like a nice, focused topic to start this meeting. So many drugs,
More informationDroperidol has comparable clinical efficacy against both nausea and vomiting
British Journal of Anaesthesia 103 (3): 359 63 (2009) doi:10.1093/bja/aep177 Advance Access publication July 15, 2009 has comparable clinical efficacy against both nausea and vomiting C. C. Apfel 1 *,
More information4/18/2018. Disclosure. Learning Objectives. St. Vincent Healthcare. Supportive Literature. Background
Implementation of a risk-score-dependent antiemetic protocol to reduce post-operative nausea and vomiting (PONV) in inpatient surgical patients Eugene P. Eldridge, PharmD, RPh PGY-1 Pharmacy Resident St.
More informationComparison of Drugs and Intravenous Crystalloid in Reduction of Postoperative Nausea and Vomiting after Laparoscopic Surgery
Comparison of Drugs and World Intravenous Journal of Crystalloid Laparoscopic in Reduction Surgery, of January-April Postoperative 2008;1(1):29-34 Nausea and Vomiting after Lap Surgery Comparison of Drugs
More informationThe Journal of International Medical Research 2011; 39:
The Journal of International Medical Research 2011; 39: 399 407 A Randomized, Double-blind Trial of Palonosetron Compared with Ondansetron in Preventing Postoperative Nausea and Vomiting after Gynaecological
More informationReexamining Metoclopramide s Role in the Prevention of Postoperative Nausea and Vomiting: A Secondary Analysis
Reexamining Metoclopramide s Role in the Prevention of Postoperative Nausea and Vomiting: A Secondary Analysis Amy J. Masiongale, DNP, CRNA Jane T. Garvin, PhD, RN, FNP-BC Marguerite J. Murphy, DNP, RN
More informationPostoperative nausea and vomiting
Review Article Korean J Anesthesiol 2014 September 67(3): 164-170 http://dx.doi.org/10.4097/kjae.2014.67.3.164 Postoperative nausea and vomiting Department of Anesthesiology and Pain Medicine, Seoul St.
More informationEfficacy of palonosetron for the prevention of postoperative nausea and vomiting: a randomized, double-blinded, placebo-controlled trial
British Journal of Anaesthesia 112 (3): 485 90 (2014) Advance Access publication 22 October 2013. doi:10.1093/bja/aet340 CLINICAL PRACTICE Efficacy of palonosetron for the prevention of postoperative nausea
More informationEvaluation of Three 5-HT 3
Evaluation of Three Receptor Antagonists in the Prevention of Postoperative Nausea and Vomiting in Adults Shan Wang, PharmD, Joseph Greco, MD, Reena A. Joseph, PharmD Candidate, Martin Feuerman, MS, and
More informationBreast Augmentation: Reducing Postoperative Nausea and Vomiting. A Prospective Study
Journal of Anesthesia & Critical Care: Open Access Breast Augmentation: Reducing Postoperative and. A Prospective Abstract Background: Breast augmentation is the plastic surgery procedure associated with
More informationPrevention of Antineoplastic Medication induced Nausea and Vomiting in Pediatric Cancer Patients
Prevention of Antineoplastic Medication induced Nausea and Vomiting in Pediatric Cancer Patients Done by :Meznah Zaid Al-Mutairi Pharm.D Candidate PNU University College of Pharmacy Introduction Nausea
More informationAlizaprideand ondansetronin the prevention of postoperative nausea and vomiting: a prospective, randomized, double-blind, placebocontrolled
Alizaprideand ondansetronin the prevention of postoperative nausea and vomiting: a prospective, randomized, double-blind, placebocontrolled trial. M. Smets N. Van Langenhove G. Dewinter Vrijdagochtendkrans22
More informationPONV and The Role of Therapeutic Decision Support
PONV and The Role of Therapeutic Decision Support Joseph V. Pergolizzi, Jr., M.D. Adjunct Assistant Professor Johns Hopkins University Naples Anesthesia and Pain Associates Naples, Florida Editor-in Chief
More informationPostoperative nausea and vomiting prophylaxis: The efficacy of a novel antiemetic drug (palonosetron) combined with dexamethasone
Egyptian Journal of Anaesthesia (2013) 29, 117 123 Egyptian Society of Anesthesiologists Egyptian Journal of Anaesthesia www.elsevier.com/locate/egja www.sciencedirect.com Research Article Postoperative
More informationSECTION 1: FEELING SICK
Risks associated with your anaesthetic SECTION 1: This leaflet explains the causes of sickness following anaesthesia and surgery, what can text be done to prevent it occurring, and treatments available
More informationATTUALITÀ NEL CONTROLLO DELL EMESI
ATTUALITÀ NEL CONTROLLO DELL EMESI Dr Claudio Lotesoriere Dipartimento di Oncoematologia S.C. di Oncologia Medica P.O. San G. Moscati TARANTO email oncologia.taranto@gmail.com Types of CINV: Definitions
More informationAntiemetic Prophylaxis for Office-based Surgery
CLINICAL INVESTIGATIONS Anesthesiology 2003; 98:293 8 2003 American Society of Anesthesiologists, Inc. Lippincott Williams & Wilkins, Inc. Antiemetic Prophylaxis for Office-based Surgery Are the 5-HT 3
More informationSymptom Management. Thomas McKain, MD, ABFM, ABHPM Medical Director
Symptom Management Nausea & Vomiting Thomas McKain, MD, ABFM, ABHPM Medical Director Mr. Jones has nausea and vomiting. May I initiate Compazine from the Comfort Pak? Objectives 1. Delineate the Differential
More informationIs lorazepam effective at preventing nausea and vomiting after laparoscopic cholecystectomy? A randomized controlled trial
(Acta Anaesth. Belg., 2017, 68, 131-135) Is lorazepam effective at preventing nausea and vomiting after laparoscopic cholecystectomy? A randomized controlled trial F. Javaherforoosh Zadeh (*), A. Ghomeishi
More informationEfficacy of a single-dose ondansetron for preventing post-operative nausea and vomiting
European Review for Medical and Pharmacological Sciences 2001; 5: 59-63 Efficacy of a single-dose ondansetron for preventing post-operative nausea and vomiting after laparoscopic cholecystectomy with sevoflurane
More informationOndansetron and Extrapyramidal Effects. Rachel Lengle DNP, CRNA
Ondansetron and Extrapyramidal Effects Rachel Lengle DNP, CRNA Objectives! Educate the peri-operative nurse regarding the extrapyramidal side effects of ondansetron.! Provide current pharmacological review
More informationPrevention CINV (highly emetogenic) Prevention PONV
Reviews/Evaluations 5-Hydroxytryptamine3 (5-HT3) Receptor Antagonists Generic Name Brand Name Manufacturer Dolasetron Anzemet Aventis Granisetron Kytril Roche Ondansetron Zofran GlaxoSmithKline I. FDA
More informationNausea. Assessment & Management. R J Crossno, MD, CMD, FAAFP, FAAHPM. Disclosures
Nausea Assessment & Management R J Crossno, MD, CMD, FAAFP, FAAHPM Disclosures Dr. Crossno discloses his employment as Area Medical Director for VistaCare VistaCare has provided commercial support for
More informationDexamethasone combined with other antiemetics for prophylaxis after laparoscopic cholecystectomy
Original Research Article Dexamethasone combined with other antiemetics for prophylaxis after laparoscopic cholecystectomy T. Uma Maheswara Rao * Associate Professor, Department of Surgery, Konaseema Institute
More informationEffects of palonosetron and ondansetron on preventing nausea and vomiting after laparoscopic surgery
Clinical Report Effects of palonosetron and ondansetron on preventing nausea and vomiting after laparoscopic surgery Journal of International Medical Research 2018, Vol. 46(1) 411 420! The Author(s) 2017
More informationDrug Class Review on Newer Antiemetics
Drug Class Review on Newer Antiemetics Final Report January 2006 A literature scan of this topic is done periodically The purpose of this report is to make available information regarding the comparative
More informationClinical Research INTRODUCTION. Gwieun Yeo 1, Mi Kyoung Lee 1, Heezoo Kim 1, Myounghoon Kong 1, Hyo Jung Son 2, and Han Byeol Oh 2
Anesth Pain Med 2018;13:256-263 https://doi.org/10.17085/apm.2018.13.3.256 pissn 1975-5171 ㆍ eissn 2383-7977 Clinical Research Received November 17, 2017 Revised 1st, January 29, 2018 2nd, March 15, 2018
More informationKEYWORDS Obstetric Patient, Spinal Anesthesia, PONV (Post-Operative Nausea and Vomiting), Inj. Metoclopramide, Inj. Ondansetron.
PREVENTION OF POSTOPERATIVE NAUSEA AND VOMITING IN ELECTIVE LSCS UNDER SPINAL ANAESTHESIA BY PRE-OPERATIVE ONDANSETRON VERSUS METOCLOPRAMIDE: A PROSPECTIVE SINGLE-BLINDED RANDOMISED CONTROL TRIAL Prasada
More informationISSN X (Print) India. *Corresponding author Dr. D. Shiva Prasad
Scholars Journal of Applied Medical Sciences (SJAMS) Sch. J. App. Med. Sci., 2015; 3(9C):3311-3315 Scholars Academic and Scientific Publisher (An International Publisher for Academic and Scientific Resources)
More informationSatisfactory Analgesia Minimal Emesis in Day Surgeries. (SAME-Day study) A Randomized Control Trial Comparing Morphine and Hydromorphone
Satisfactory Analgesia Minimal Emesis in Day Surgeries (SAME-Day study) A Randomized Control Trial Comparing Morphine and Hydromorphone HARSHA SHANTHANNA ASSISTANT PROFESSOR ANESTHESIOLOGY MCMASTER UNIVERSITY
More informationOriginal Article Antiemetics in Prolong Surgeries Pak Armed Forces Med J 2015; 65(3):353-57
Original Article Antiemetics in Prolong Surgeries Pak Armed Forces Med J 2015; 65(3):353-57 POST OPERATIVE NAUSEA AND VOMITING [PONV]: COMPARISON OF TIMING OF ADMINISTRATION OF ANTIEMETICS IN PROLONG SURGERIES
More informationJMSCR Vol 07 Issue 04 Page April 2019
www.jmscr.igmpublication.org Index Copernicus Value: 79.54 ISSN (e)-2347-176x ISSN (p) 2455-0450 DOI: https://dx.doi.org/10.18535/jmscr/v7i4.76 A study to compare the antiemetic efficacy of ondansetron
More informationOndansetron, a selective blocking agent of the. Timing of ondansetron administration to prevent postoperative nausea and vomiting
Timing of ondansetron administration to prevent postoperative nausea and vomiting NORMA I. CRUZ, MD*; PETER PORTILLA, MD ; ROSENDO E. VELA, MD Background: The original guidelines for using ondansetron
More informationIs Intravenous Ramosetron 0.3 mg Effective In The Prevention Of Postoperative Nausea And Vomiting In Women Undergoing Gynecologic Surgery?
Philadelphia College of Osteopathic Medicine DigitalCommons@PCOM PCOM Physician Assistant Studies Student Scholarship Student Dissertations, Theses and Papers 2012 Is Intravenous Ramosetron 0.3 mg Effective
More informationManagement of post-strabismus nausea and vomiting in children using ondansetron: a value-based comparison of outcomes 1^
British Journal of Anaesthesia 89 (3): 473-8 (2002) Management of post-strabismus nausea and vomiting in children using ondansetron: a value-based comparison of outcomes 1^ B. Sennaraj 1, D. Shende 1,
More informationIf we are going to treat this, of course it's like most things, we want to treat the underlying cause as well as the effect.
Systemic Management of Nausea: Antiemetics Bruce Flint O.D. Antiemetics: This is for controlling nausea and vomiting. These are multiple conditions that's causing this. It's kind of common. I'm sure all
More informationIJMDS January 2017; 6(1) Dr Robina Makker Associate professor 2 Dr Amit Bhardwaj
Original Article Comparative efficacy of ondansetron versus granisetron to prevent perioperative nausea and vomiting in patients undergoing gynaecological surgery under spinal anaesthesia Makker R 1, Bhardwaj
More informationTRANSPARENCY COMMITTEE OPINION. 31 January Date of marketing authorisation: 22 March 2005 (centralised marketing authorisation)
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 31 January 2007 ALOXI 250 µg solution for injection B/1 CIP 375,482-8 Applicant: THERABEL LUCIEN PHARMA palonosetron
More informationPost-operative nausea and vomiting after gynecologic laparoscopic surgery: comparison between propofol and sevoflurane
Clinical Research Article Korean J Anesthesiol 2011 January 60(1): 36-40 DOI: 10.4097/kjae.2011.60.1.36 Post-operative nausea and vomiting after gynecologic laparoscopic surgery: comparison between propofol
More informationPREVENTION OF CHEMOTHERAPY INDUCED NAUSEA AND VOMITING IN ELDERLY CANCER PATIENTS JØRN HERRSTEDT, M.D. COPENHAGEN UNIVERSITY HOSPITAL HERLEV, DENMARK
PREVENTION OF CHEMOTHERAPY INDUCED NAUSEA AND VOMITING IN ELDERLY CANCER PATIENTS JØRN HERRSTEDT, M.D. COPENHAGEN UNIVERSITY HOSPITAL HERLEV, DENMARK HISTORY OF ANTIEMETICS 1979 A corticosteroid is superior
More informationBalanced Analgesia With NSAIDS and Coxibs. Raymond S. Sinatra MD, Ph.D
Balanced Analgesia With NSAIDS and Coxibs Raymond S. Sinatra MD, Ph.D Prostaglandins and Pain The primary noxious mediator released from damaged tissue is prostaglandin (PG) PG is responsible for nociceptor
More informationPalonosetron versus ondansetron as rescue medication for postoperative nausea and vomiting: a randomized, multicenter, open-label study
Candiotti et al. BMC Pharmacology and Toxicology 2014, 15:45 http://www.biomedcentral.com/2050-6511/15/45 RESEARCH ARTICLE Open Access Palonosetron versus ondansetron as rescue medication for postoperative
More informationTRIALS. Sergio Bergese 1*, Adolfo Viloria 1, Alberto Uribe 1, Alejandra Antor 1 and Soledad Fernandez 2
Bergese et al. Trials 2012, 13:130 TRIALS STUDY PROTOCOL Open Access Aprepitant versus ondansetron in preoperative triple-therapy treatment of nausea and vomiting in neurosurgery patients: study protocol
More informationManagement of Chemotherapy Induced Nausea/Vomiting(CINV) in Adult Cancer Patients
Management of Chemotherapy Induced Nausea/Vomiting(CINV) in Adult Cancer Patients By Zahra Shaghaghi, Pharm-D, BCOP, PhC Prepared for 2018 NMSHP Balloon Fiesta Symposium Goals and Objectives: Describe
More informationManagement of Chemotherapy Induced Nausea/Vomiting(CINV) in Adult Cancer Patients
Management of Chemotherapy Induced Nausea/Vomiting(CINV) in Adult Cancer Patients By Zahra Shaghaghi, Pharm-D, BCOP, PhC Prepared for 2018 NMSHP Balloon Fiesta Symposium 1 Goals and Objectives: Describe
More informationManaging Adverse Events in the Cancer Patient. Learning Objectives. Chemotherapy-Induced Nausea/Vomiting
Managing Adverse Events in the Cancer Patient Lisa A Thompson, PharmD, BCOP Assistant Professor University of Colorado Skaggs School of Pharmacy and Pharmaceutical Sciences Learning Objectives Describe
More informationIncidence of and risk factors for postoperative nausea and vomiting at a Japanese Cancer Center: first large-scale study in Japan
J Anesth (2013) 27:18 24 DOI 10.1007/s00540-012-1468-5 ORIGINAL ARTICLE Incidence of and risk factors for postoperative nausea and vomiting at a Japanese Cancer Center: first large-scale study in Japan
More informationWon-Suk Lee 1, Kwang-Beom Lee 2, Soyi Lim 2 and Young Gin Chang 3*
Lee et al. BMC Anesthesiology (2015) 15:121 DOI 10.1186/s12871-015-0102-0 RESEARCH ARTICLE Open Access Comparison of palonosetron, granisetron, and ramosetron for the prevention of postoperative nausea
More informationOpioid-free total intravenous anaesthesia reduces postoperative nausea and vomiting in bariatric surgery beyond triple prophylaxis
British Journal of Anaesthesia 112 (5): 906 11 (2014) Advance Access publication 18 February 2014. doi:10.1093/bja/aet551 Opioid-free total intravenous anaesthesia reduces postoperative nausea and vomiting
More informationRemifentanil. Addressing the challenges of ambulatory orthopedic procedures 1-3
Remifentanil Addressing the challenges of ambulatory orthopedic procedures 1-3 INDICATIONS AND IMPORTANT RISK INFORMATION INDICATIONS ULTIVA (remifentanil HCl) for Injection is indicated for intravenous
More informationDhawal R. Wadaskar*, Jyoti S. Magar, Bharati A. Tendolkar
International Journal of Research in Medical Sciences Wadaskar DR et al. Int J Res Med Sci. 2016 Aug;4(8):3191-3197 www.msjonline.org pissn 2320-6071 eissn 2320-6012 Research Article DOI: http://dx.doi.org/10.18203/2320-6012.ijrms20162214
More informationA comparative study of the antiemetic efficacy of dexamethasone, ondansetron, and metoclopramide in patients undergoing gynecological surgery
Med Sci Monit, 2010; 16(7): CR336-341 PMID: 20581776 WWW.MEDSCIMONIT.COM Clinical Research Received: 2008.04.25 Accepted: 2009.05.31 Published: 2010.07.01 A comparative study of the antiemetic efficacy
More informationPrevention Management of Postoperative Nausea and Vomiting in Ambulatory Setting: How Well are We Identifying Patients with Motion Sickness?
Rhode Island College Digital Commons @ RIC Master's Theses, Dissertations, Graduate Research and Major Papers Overview Master's Theses, Dissertations, Graduate Research and Major Papers 5-1-2013 Prevention
More informationClinical Policy: Ondansetron (Zuplenz) Reference Number: CP.PMN.45 Effective Date: Last Review Date: Line of Business: Medicaid
Clinical Policy: (Zuplenz) Reference Number: CP.PMN.45 Effective Date: 09.01.06 Last Review Date: 02.19 Line of Business: Medicaid Revision Log See Important Reminder at the end of this policy for important
More informationComparison of surgical site and patient s history with a simplified risk score for the prediction of postoperative nausea and vomiting
Comparison of surgical site and patient s history with a simplified risk score for the prediction of postoperative nausea and vomiting C. C. Apfel, 1,2 P. Kranke 2 and L. H. J. Eberhart 3 1 Department
More informationManagement of Nausea and Vomiting
June 01, 2015 By Rudolph M. Navari, MD, PhD, FACP [1] Although marked progress in controlling chemotherapy-induced emesis has occurred over the past 25 years, nausea and vomiting remain among the most
More informationGeneral anesthetics. Dr. Shamil AL-Noaimy Lecturer of Pharmacology Dept. of Pharmacology College of Medicine
General anesthetics Dr. Shamil AL-Noaimy Lecturer of Pharmacology Dept. of Pharmacology College of Medicine Rationale General anesthesia is essential to surgical practice, because it renders patients analgesic,
More informationClinical Study Effective Dose of Ramosetron for Prophylaxis of Postoperative Nausea and Vomiting in High-Risk Patients
BioMed Research International Volume 2015, Article ID 951474, 6 pages http://dx.doi.org/10.1155/2015/951474 Clinical Study Effective Dose of Ramosetron for Prophylaxis of Postoperative Nausea and Vomiting
More informationWhy Patients Experience Nausea and Vomiting and What to Do About It
Why Patients Experience Nausea and Vomiting and What to Do About It Rebecca Clark-Snow, RN, BSN, OCN The University of Kansas Cancer Center Westwood, Kansas Multiple Roles for Supportive Care in Cancer
More informationUpdates in Chemotherapy-Induced Nausea and Vomiting (CINV) 2017
Updates in Chemotherapy-Induced Nausea and Vomiting (CINV) 2017 MELISSA C. MACKEY, PHARMD, BCPS, BCOP ONCOLOGY CLINICAL PHARMACIST DUKE UNIVERSITY HOSPITAL AUGUST 5, 2017 Objectives Review risk factors
More informationDexamethasone Compared with Metoclopramide in Prevention of Postoperative Nausea and Vomiting in Orthognathic Surgery
Article ID: WMC002013 2046-1690 Dexamethasone Compared with Metoclopramide in Prevention of Postoperative Nausea and Vomiting in Orthognathic Surgery Corresponding Author: Dr. Agreta Gashi, Anesthesiologist,
More informationCurrent evidence in acute pain management. Jeremy Cashman
Current evidence in acute pain management Jeremy Cashman Optimal analgesia Best possible pain relief Lowest incidence of side effects Optimal analgesia Best possible pain relief Lowest incidence of side
More informationProphylactic use of dexamethasone in tonsillectomy among children
Prophylactic use of dexamethasone in tonsillectomy among children Author(s): Ali Maeed Al-Shehri Vol. 11, No. 1 (2007-10 - 2007-12) Curr Pediatr Res 2007; 11 (1 & 2): 3-7 Ali Maeed Al-Shehri Department
More informationSetting The setting was secondary care. The economic study was carried out in the USA.
The effect of timing of ondansetron administration on its efficacy, cost-effectiveness, and cost-benefit as a prophylactic antiemetic in the ambulatory setting Tang J, Wang B G, White P F, Watcha M F,
More informationThe management of acute surgical pain has
Intravenous Dexamethasone as an Analgesic: A Literature Review Sean G. Moore, MSN, CRNA The management of pain in surgical patients has shifted in recent years from a technique grounded in opioid administration,
More informationA Comparative Clinical Study Of Prevention Of PostOperative Nausea And Vomiting Using Granisetron And
ISPUB.COM The Internet Journal of Anesthesiology Volume 26 Number 1 A Comparative Clinical Study Of Prevention Of PostOperative Nausea And Vomiting Using Granisetron And Ondansetron In Laparoscopic Surgeries.
More informationAntiemetic and analgesic-sparing effects of diphenhydramine added to morphine intravenous patient-controlled analgesia
British Journal of Anaesthesia 94 (6): 835 9 (2005) doi:10.1093/bja/aei137 Advance Access publication April 15, 2005 Antiemetic and analgesic-sparing effects of diphenhydramine added to morphine intravenous
More informationIncidence of Postoperative Nausea and Vomiting in Dr. Hasan Sadikin General Hospital Bandung Period May to October 2013
58 AMJ March 2017 Incidence of Postoperative Nausea and Vomiting in Dr. Hasan Sadikin General Hospital Bandung Period May to October 2013 Aisyah Ummu Fahma, 1 Iwan Fuadi, 2 Jimmy Setiadinata 3 1 Faculty
More informationPostoperative nausea (PON) is a frequent complication
Efficacy of Acupuncture in Prevention of Postoperative Nausea in Cardiac Surgery Patients Yuliya Korinenko, MD, Ann Vincent, MD, Susanne M. Cutshall, CNS, Zhuo Li, MS, and Thoralf M. Sundt III, MD Mayo
More informationISPUB.COM. A Wadaskar, N Swarnkar, A Yadav INTRODUCTION METHODS
ISPUB.COM The Internet Journal of Anesthesiology Volume 20 Number 1 Granisetron has superior control over postoperative nausea and vomiting than ondansetron in gynecological surgeries: a placebo controlled
More informationShow Me the Evidence: Epidurals, PVBs, TAP Blocks Christopher L. Wu, MD Professor of Anesthesiology The Johns Hopkins Hospital
Show Me the Evidence: Epidurals, PVBs, TAP Blocks Christopher L. Wu, MD Professor of Anesthesiology The Johns Hopkins Hospital Overview Review overall (ERAS and non-eras) data for EA, PVB, TAP Examine
More informationDrug Use Criteria: Oral Serotonin 5-HT3 Receptor Antagonists for Nausea and Vomiting
Texas Vendor Drug Program Drug Use Criteria: Oral Serotonin 5-HT3 Receptor Antagonists for Nausea and Vomiting Publication History Developed September 1996. Revised July 2018; September 2016; June 2015;
More informationAnesthesia for OutPatient Spine Surgery. Michael A. Kellams, D.O.
Anesthesia for OutPatient Spine Surgery Michael A. Kellams, D.O. DISCLOSURE None! Hot Topics 2017 -Multimodal Analgesia/ERAS -TAP block -Inpatient procedures outpatient (Fusions) Multimodal Analgesia -Using
More informationEun Jin Ahn, 1 Geun Joo Choi, 2 Hyun Kang, 2 Chong Wha Baek, 2 Yong Hun Jung, 2 and Young Cheol Woo Introduction. 2. Materials and Methods
Hindawi BioMed Research International Volume 2017, Article ID 9341738, 6 pages https://doi.org/10.1155/2017/9341738 Research Article Comparison of Ramosetron with Palonosetron for Prevention of Postoperative
More informationEffect of Intraoperative Dextrose Infusion for Prevention of Postoperative Nausea and Vomiting in Diagnostic Gynecologic Laparoscopy
http://www.cjmb.org Open Access Original Article Crescent Journal of Medical and Biological Sciences Vol. 5, No. 1, January 2018, 45 49 eissn 2148-9696 Effect of Intraoperative Dextrose Infusion for Prevention
More informationFirst a caution. Processes we might NOT try to treat with medications. Processes we might try to treat. Main drug categories.
Pharmacological Interventions for dizziness Timothy C. Hain, MD Northwestern University Medical School Chicago, Illinois, USA First a caution Torok N. Old and new in Meniere's disease. Laryngoscope 87:1870-1877,
More informationAnesthesia For The Elderly. Yasser Sakawi, M.D. Associate Professor Anesthesiology Department
Anesthesia For The Elderly Yasser Sakawi, M.D. Associate Professor Anesthesiology Department Topics of Discussion General concepts and definitions Aging and general organ function Cardiopulmonary function
More informationLOW DOSE INTRAVENOUS MIDAZOLAM FOR PREVENTION OF PONV, IN LOWER ABDOMINAL SURGERY
LOW DOSE INTRAVENOUS MIDAZOLAM FOR PREVENTION OF PONV, IN LOWER ABDOMINAL SURGERY - Preoperative vs Intraoperative Administration - Mohammad Reza Safavi * and Azim Honarmand ** Abstract Background: The
More informationERAS: Enhanced Recovery After Surgery. Christopher L. Wu, M.D. Professor of Anesthesiology The Johns Hopkins University; Baltimore, Maryland
ERAS: Enhanced Recovery After Surgery Christopher L. Wu, M.D. Professor of Anesthesiology The Johns Hopkins University; Baltimore, Maryland Overview History and basic principles of ERAS Review published
More informationReceived: 29/05/2017 Revised: 11/09/2017 Accepted: 26/07/2017 ABSTRACT
International Journal of Medical Science and Education An official Publication of Association for Scientific and Medical Education (ASME) Original research Article PREOPERATIVE PALONOSETRON AND DEXAMETHASONE
More informationNerve Blocks & Long Acting Analgesia for Plastic Surgeons. Karol A Gutowski, MD, FACS
Nerve Blocks & Long Acting Analgesia for Plastic Surgeons Karol A Gutowski, MD, FACS Disclosures None related to this topic Why is Non-Opioid Analgesia Important Opioid epidemic Less opioid use Less PONV
More informationNeuro Basics SLO Practice (online) Page 1 of 5
Neuro Basics SLO Practice (online) Page 1 of 5 1) Biogenic amines include ACh, NE, EPI and? a) Melatonin b) Dopamine c) Serotonin d) Histamine e) All of the neurotransmitters listed are biogenic amines.
More informationAmerican Journal of Oral Medicine and Radiology
American Journal of Oral Medicine and Radiology e - ISSN - XXXX-XXXX ISSN - 2394-7721 Journal homepage: www.mcmed.us/journal/ajomr COMPARISON OF ONDANSETRON V/S RAMOSETRON FOR PREVENTION OF POST OPERATIVE
More information